Strong early durability supports Fisera, but pivotal execution and regulatory validation remain decisive.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-03-30 |
| Length | 36 minutes |
| EPS | $-0.68 |
| EPS consensus | $-0.72 |
| Revenue | $3.8M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26
Read the full Q4 FY25 earnings call transcript
All BCAX earnings · Back to BCAX overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.